AbbVie (ABBV) Long-Term Deferred Tax (2013)

AbbVie (ABBV) posted quarterly Long-Term Deferred Tax of -$582.0 million for Q3 2013.

AbbVie (ABBV) Long-Term Deferred Tax (2013) Analysis & Trends

AbbVie (ABBV) has reported Long-Term Deferred Tax for 1 consecutive years, with -$582.0 million the latest figure, recorded in Q3 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data

Date	Value
Sep 30, 2013	-582.00 Mn